Thorne Research, Inc. and Helsinn have jointly announced the launch OncoQOL™, a product line consisting of 13 nutritional supplements formulated to support the unique nutritional needs of patients undergoing cancer treatment. The OncoQOL portfolio also includes the DermaQOL™ product line, with nine personal care products specially formulated to support the skin-care and hair-care needs of patients undergoing cancer treatment. DermaQOL products are manufactured using only high-quality, certified organic ingredients. OncoQOL products, including the DermaQOL product line, are available only through oncologists and other medical professionals in the United States and Canada.
 
Treatment for cancer often results in nutritionally related undesirable effects, such as weight loss, fatigue, diarrhea, and highly sensitive nerves and skin. The OncoQOL product line is designed to help patients address these and other similar conditions which can deteriorate their quality of life and adversely affect compliance in fully completing their course of treatment.
 
“For many cancer patients the side effects of treatment have a significant impact on their health and quality of life, often making it difficult for them to continue with their therapy. Our products are designed to meet the unique needs of these patients and are manufactured with the essential levels of purity and consistency that are so important for this population,” said Sreenivas Rao, MD, president, OncoQOL.
 
OncoQOL nutritional supplement products are manufactured using pure, hypoallergenic, highly-absorbable nutrients. All products undergo extensive quality control testing during every phase of the manufacturing process. Although some of their active ingredients have been clinically shown to provide important benefits to cancer patients, OncoQOL products are not intended to treat specific diseases and should not be considered as adjuncts to disease treatment.